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Although placebo analgesia is a well-recognized phenomenon with important 
clinical implications, the possibility that placebo effects occur during sleep has 
received little attention. This experimental study examined whether 
responsiveness to acute heat pain stimuli applied during sleep could be reduced 
following a placebo conditioning procedure administered before sleep. Healthy 
individuals (n=9) underwent polysomnographic recordings for one habituation 
night followed by one placebo analgesia night and one control night in 
counterbalanced order. Conditioning induced robust analgesia expectations 
before the placebo night. In the morning after the placebo night, participants 
reported less nocturnal pain, anxiety, and associated sleep disturbance (all 
p’s<0.05) compared to the control night. Furthermore, placebo induction 
produced a 10% reduction in brain arousals evoked by noxious stimuli during 
rapid-eye-movement (REM) sleep (p=0.03), consistent with our previous findings 
suggesting that analgesia expectations are reprocessed during REM sleep. In 
contrast, arousals increased by 14% during slow wave sleep (SWS) (p=0.02). In 
the morning after the last recording night, placebo testing administered as a 
manipulation check confirmed that typical placebo analgesic responses were 
produced during waking (p’s<0.05). These results suggest that analgesia 
expectations developed before sleep reduced nocturnal pain perception and 
subjective sleep disturbances and activated brain processes that modulate 
incoming nociceptive signals differentially according to sleep stage. These results 
need to be replicated in future studies exploring how analgesia expectations may 
be reactivated during different sleep stages to modulate nociceptive responses.  






Expectations have a profound influence on human perception. In the waking 
state, placebo analgesia is an example of cognitive modulation driven by 
expectations of a positive treatment outcome (e.g., [1;8;16;42;52;64]). Although 
classical conditioning appears sufficient to generate placebo responses involving 
unconscious physiological functions, the modulation of pain perception by a 
placebo generally involves a conscious anticipation of relief ([9;15]).  
 
Sleep is a state of reduced awareness in which higher-order processing of 
external stimuli is generally thought to be largely suppressed. Given that 
conscious processing of placebo cues and associated outcomes may be 
necessary for placebo responses to occur, placebo effects would be expected to 
be suppressed during sleep. However, once learning has occurred, expectancy 
may affect later outcomes through unconscious processes ([28;31;43]). Learned 
placebo analgesia responses might then be expressed without explicit 
processing of pain-related cues or conscious evocation of relief expectancy. 
 
The brain may process external stimuli during both rapid-eye-movement sleep 
(REM) and slow-wave sleep (SWS), and the reduced engagement of frontal 
cortices in response to such inputs is generally interpreted as a sleep-protecting 
function that prevents waking ([14;18;56;63]). Brain activity during REM sleep 
has also been associated with cognitive processes ([19;25;38;49]), including 
offline reprocessing of recent memories ([36;59]). We previously suggested that 
REM sleep may be involved in the reprocessing of relief expectations generated 
prior to sleep ([33;34]). Placebo mechanisms may involve sleep-related 
processing that results from unconscious reactivation of learned expectations 
that may alter responses to noxious stimuli. 
 
In the present study, healthy participants underwent placebo conditioning on the 
evening before sleep and were subjected to noxious thermal stimuli while 




sleeping the following night. We tested the hypothesis that placebo conditioning 
and relief expectations induced prior to sleep would reduce nocturnal pain, 
anxiety, and sleep disturbance reported the following morning. Polysomnography 
was used to assess brain arousals in response to nociceptive stimuli across 
sleep stages. We expected a reduction in stimulus-induced arousals during 
sleep, and especially during REM sleep, in response to a possible reactivation of 
relief expectations. 
 
2. MATERIALS AND METHODS 
 
2.1 Participants  
 
Eleven participants were recruited from the University of Montreal campus, and 
all procedures were conducted in a sleep laboratory at the Centre for Advanced 
Research in Sleep Medicine of the Hôpital du Sacré-Coeur de Montréal 
(http://www.ceams-carsm.ca/en). Data from one participant were incomplete due 
to equipment failure, and data from another one were discarded due to unreliable 
pain reports in the calibration phases (see below). The final data set included 9 
healthy right-handed volunteers (5 females, mean age = 22.8 ± 0.6 years) free of 
medication except for contraceptive pills for 3 women. Participants had a regular 
sleep–wake cycle (7–8 hours per night, with bedtime between 10:00 PM and 
12:00 AM), which they maintained during the entire course of the study. They 
were asked to abstain from alcohol and caffeine 24 h before and during each of 
the 3 testing sessions. All experimental procedures met the guidelines of the 
latest revision of the Declaration of Helsinki and were approved by the 
Institutional Research Ethics Board. All participants signed a consent form and 
were debriefed at the end of the study.  
 




2.2 Procedures and Design 
 
Contact heat pain was induced on the ventral forearm with a 3 cm2 thermal probe 
(TSA-II NeuroSensory Analyzer; Medoc Ltd.). Heat stimuli lasted 17 s, including 
a 7 s plateau at the target temperature and two 5 s up/down ramps from/to a 
baseline temperature of 32°C. In waking state, successive stimuli were preceded 
by a 5 s auditory countdown and separated by a 60 s interval. In the calibration 
blocks (a total of 6, Figure 1), sequences of ascending stimuli (1°C increments) 
were delivered to each arm starting at 41°C up to the participant’s tolerance 
threshold or a maximum of 50°C. The pain produced by each stimulus was rated 
on a visual analog scale (VAS; see below) and a stimulus-response function was 
obtained for each participant to determine the individual temperatures 
administered in the placebo conditioning and placebo phases.  
 
The within-subject design included three overnight sessions from about 8:00 PM 
to 9:00 AM (Figure 1). The first and second sessions took place on consecutive 
nights, with the third session one week later. The first session served as a 
habituation night to acclimatize participants to the sleep laboratory and to initiate 
placebo conditioning. In the conditioning block for the first session, the same inert 
cream was applied to the control and placebo site. The cream was described to 
the participant as a long-lasting topical analgesic when applied to the placebo 
site, and an inert compound when applied to the control site. A series of 8 stimuli 
were then administered to each site. Stimulus intensity at the control site was 
adjusted based on the first calibration block to produce moderate pain 
(corresponding to a rating of 40–60/100 VAS intensity units). At the placebo site, 
stimulus intensity was surreptitiously decreased by 2°C. Expected, concurrent, 
and retrospective pain ratings were collected for each site (see below). 
Participants were then prepared for polysomnographic recording with standard 
electroencephalographic (EEG), electrooculographic, and electromyographic 
settings. Participants were informed that no thermal stimuli would be applied 




during the first night. The light was turned off at 11:00 PM, and participants were 
woken up at 7:00 AM. 
 
 
Figure 1. Experimental design. Six thermal calibration blocks were 
performed in the evening and morning of each of the three nights spent in 
the laboratory to control for potential differences in pain sensitivity. A 
conditioning procedure was administered before each night to generate 
robust experience-driven expectations of pain relief by the placebo 
treatment. No nocturnal thermal stimuli were administered during the first 
night (habituation). Control and placebo conditions were administered in 
the second and third nights (counterbalanced between participants), and 
nociceptive heat stimuli of the same intensity were administered during 
both nights across REM and non-REM sleep stages. Placebo analgesia 
was assessed  in waking state after the calibration block on the last 
morning. Arrows represent nociceptive stimuli. 
 
 
In the experimental sessions (control and placebo nights), nociceptive stimuli 
were administered with a contact probe stably attached to the participant’s 
forearm. To avoid alerting participants to incoming stimuli, the apparatus was 
placed in an adjacent room and connected to the probe via a long cable passing 




through a wall opening. Just before sleep on the control night, only the neutral 
cream described as inert was applied to the control site, followed by 8 stimuli at 
moderate pain intensity according to the calibration phase. Just before sleep on 
the placebo night, the same cream was applied to the placebo site, but with the 
suggestion that it would provide long-lasting analgesia. Eight stimuli were then 
delivered to the placebo site with intensity surreptitiously reduced by 2°C below 
that for the control site. The light was turned off at 11:00 PM. Nocturnal heat 
stimuli of equal intensity, corresponding to moderate pain, were applied on the 
control and placebo nights. Stimuli were delivered pseudorandomly across stage 
2, SWS, and REM sleep to obtain comparable distributions between the two 
nights. The first stimulus was delivered after participants attained the first stable 
period of SWS. Stimuli were then administered after a sleep stage was stable for 
at least 2 minutes and at intervals of at least 2 minutes. Participants were woken 
up at 7:00 AM and the calibration procedure was repeated. 
 
On the morning of the last session, a placebo test block was conducted in waking 
state after the final calibration. The placebo and control creams were reapplied 
and the conditioning block procedure used on the habituation night was 
repeated, but with 5 stimuli of equal intensity (moderate pain) applied to both 
sites. Expected, concurrent, and retrospective subjective pain ratings were 
collected for each site to confirm the placebo effect in waking state (i.e., 
manipulation check). 
 
2.3 Subjective Ratings 
 
Subjective ratings of pain intensity and unpleasantness (expected, concurrent, 
and retrospective) were acquired with a 15 cm VAS ([51]) translated into French. 
The descriptors “no pain sensation” and “most intense pain imaginable” and “not 
at all unpleasant” and “most unpleasant imaginable” were used as anchors on 
the pain intensity and unpleasantness scales, respectively. Expected pain 
intensity and unpleasantness were obtained by asking, “What do you expect the 




pain intensity/unpleasantness to be without/with the analgesic cream?” 
Concurrent ratings of pain intensity and unpleasantness were obtained after each 
stimulus using the same scales. Retrospective ratings were acquired 
approximately 2 min after each block completion by asking, “Retrospectively, 
what was the overall pain intensity/unpleasantness you felt without/with the 
analgesic cream?”  
 
Just before the light was turned off on the control and placebo nights, 
expectations of nocturnal pain, sleep disturbance, and anxiety were assessed 
with the following questions: “What do you expect the pain 
intensity/unpleasantness to be during the night?”; “How much do you expect the 
experimental pain to disturb your sleep?”; and “When you think of the coming 
night, how would you rate your anxiety?” At morning wake-up, participants were 
asked to retrospectively rate their nocturnal experience on the same scales in 
response to the following questions: “What was the intensity/unpleasantness of 
the pain you felt during the night?”; “How much did the experimental pain disturb 
your sleep?”; “How many stimuli do you remember feeling during the night?”; and 




Recording electrodes were placed according to the International 10-20 System 
([27;44]) and positioned at PF1, PF2, F3, F4, Fz, C3, C4, Cz, O1, and O2, with 
linked earlobes (A1 + A2) as a reference. An experienced technician installed 
and removed the electrodes and performed online monitoring of 
polysomnographic activity in an adjacent room during the night. To ensure 
blinding, the technician did not attend the calibration or conditioning phases of 
the paradigm and did not further interact with the participants or the experimenter 
during the behavioral data recording (i.e., rating and questionnaires). The 
technician was also blind to the experimental conditions during offline scoring, 
which was performed according to standard guidelines ([53]) to assess sleep 




architecture and identify responses evoked by the noxious heat stimuli during 
each sleep stage. An arousal response was recorded when a change lasting 
more than 3 s and within a 15 s window starting from stimulus onset was 
identified in the polysomnographic recordings ([3][35]).  
 
In addition, the following parameters were extracted for each of the 3 nights. 
Sleep latency was defined as the time in minutes from the moment when the light 
was turned off to the first sleep episode. Sleep duration (min) corresponded to 
the total sleep time, as determined by polysomnography. Sleep efficiency (%) 
was calculated by dividing the sleep duration by the overall time from sleep onset 
to final morning wake-up. The relative durations of stage 2 sleep, SWS (stages 3 
and 4), and REM sleep were expressed as the percentage of time spent in each 
stage relative to the total sleep time. REM sleep latency was defined as the delay 
in minutes between sleep onset and the first episode of REM sleep. 
 
2.5 Statistical Analyses 
 
Means ± SEM are presented. A 3 (sessions) x 2 (time of day) x 2 (conditions) 
ANOVA for repeated measures with Huynh–Feldt correction was used to analyze 
the calibration data. Paired T-tests were used to compare subjective ratings 
between control and placebo conditions. ANOVA for repeated measures was 
used to compare sleep parameters between the nights. Total numbers of 
stimulations per night and for each sleep stage were pooled across all 
participants and compared with paired T-tests across conditions. Yates-corrected 
Chi-square tests were used to compare proportions of  brain arousals between 
control and placebo nights [for each sleep stage. 
  






3.1 Baseline Pain Sensitivity 
 
In the evening and morning of each of the 3 sessions, all participants completed 
a calibration block to determine their moderately painful temperature and to 
assess changes in baseline pain sensitivity throughout the study. The overall 
average heat pain threshold was 44.9 ± 0.5°C, with no significant difference in 
sensitivity between control and placebo stimulus sites (45.0 ± 0.6 vs. 44.8 ± 
0.5°C; F(1,7)=0.51, p=0.50), nor between evening and morning calibration blocks 
(44.8 ± 0.6 vs. 45.0 ± 0.5°C; F(1,7)=0.36, p=0.57). Participants tended to be 
slightly more sensitive to heat pain in the habituation session (session 1: 44.3 ± 
0.7°C, session 2: 45.1 ± 0.5°C, session 3: 45.3 ± 0.5°C; F(2,14)=3.67, p=0.08), 
but no significant variation was found between control and placebo nights 
performed as the second or third session (main effect of experimental night 
order: F(1,7)=0.04, p=0.85; interaction between session and night order: 
F(2,14)=0.68, p=0.48). No other significant main effect or interaction was 
observed. 
 
Based on the first calibration block, the temperature required to induce moderate 
pain was estimated for each participant. Throughout the study, the average 
temperatures delivered to control and placebo sites in the conditioning trials were 
48.6 ± 0.2°C and 46.6 ± 0.2°C, corresponding to mean pain intensity ratings of 
46.1/100 ± 4.8 and 26.6/100 ± 3.8 VAS units, respectively.  
 
3.2 Placebo Conditioning 
 
In addition to verbal suggestions of pain relief, conditioning was used to 
strengthen participant expectations of treatment effectiveness by surreptitiously 
decreasing the temperature applied to the placebo site. In the first session, a 
conditioning block was performed with 8 stimuli at each site. Beforehand, 




participants were asked to rate how much pain they expected to feel at the 
control and placebo sites. Participants expected an average pain intensity of 33.6 
± 4.5 VAS units at the control site compared with 23.2 ± 4.9 at the placebo site 
(T(8)=4.04, p=0.004). Actual pain experienced during conditioning was also 
significantly lower at the placebo site, with an average intensity rating of 38.6 ± 
6.3 for the control site compared with 24.3 ± 4.2 for the placebo site (T(8)=4.6, 
p=0.002). Additionally, retrospective pain intensity ratings were lower for stimuli 
administered to the placebo site (42.0 ± 6.8 VAS units for the control site 
compared with 23.8 ± 4.7 VAS units for the placebo site; T(8)=5.9, p<0.001). 
Similar results were found for the averaged pain unpleasantness ratings 
(expected control vs. placebo: 27.9 ± 5.5 vs. 17.6 ± 4.7, T(8)=3.4, p=0.009; 
concurrent control vs. placebo: 34.4 ± 6.7 vs. 19.2 ± 3.7, T(8)=4.1, p=0.003; 
remembered control vs. placebo: 38.7 ± 7.2 vs. 14.8 ± 3.9, T(8)=5.4, p=0.001). 
These results indicate that the participants initially expected the placebo cream to 
reduce pain, and that conditioning produced the intended experience of 
analgesia. 
 
Before the light was turned off in the experimental sessions, participants again 
received 8 stimuli at one of the two skin sites, depending on the condition. 
Stimulus intensity was surreptitiously decreased when administered at the 
placebo site. Average pain intensity was 39.9 ± 5.5 VAS units for the control night 
compared to 16.7 ± 6.5 for the placebo night (T(8)=4.60, p=0.002, Paired T-test). 
Similar results were found for pain unpleasantness, with an average of 34.6 ± 5.6 
and 14.6 ± 6.1 for the control and placebo night, respectively (T(8)=4.66, 
p=0.002). This additional manipulation was performed immediately before sleep 
in order to re-evoke the participant’s expectation that the placebo cream would 
provide nocturnal relief. 
 




3.3 Nocturnal Placebo Effect: Subjective Ratings 
 
To assess the presence of a nocturnal placebo effect, subjective ratings were 
collected before and after sleep in both experimental sessions (Figure 2). On the 
evening of the control and placebo nights, participants were asked to assess how 
much pain they expected to feel during the night and the extent to which they 
expected the pain to disturb their sleep. On the evening of the placebo night, 
participants expected the nociceptive stimuli to produce lower nocturnal pain 
intensity (T(8)=4.85, p=0.001) and unpleasantness (T(8)=3.58, p=0.007) and 
fewer sleep disturbance (T(8)=3.12, p=0.014). Participants also reported less 
anticipatory anxiety on the placebo compared with the control night (T(8)=3.66, 
p=0.006). 
 
In the morning, participants were asked to retrospectively rate their nocturnal 
experience. Significant reductions were observed in nocturnal pain intensity 
(T(8)=3.13, p=0.014), pain unpleasantness (T(8)=3.42, p=0.009), anxiety 
(T(8)=2.44, p=0.041), and associated sleep disturbance (T(8)=3.21, p=0.012). In 
addition, participants recalled fewer stimulations on the morning of the placebo 
compared with the control night (placebo night: 3.1 ± 0.8; control night: 4.3 ± 0.7; 
T(8)=2.48, p=0.038).  
 
 





Figure 2. Subjective ratings. Ratings for expected (A) and retrospective 
(B) pain intensity (Int.) and unpleasantness (Unp.), pain-related sleep 
disturbance, and anxiety collected in the evening (expected) and morning 
(retrospective) of the control and placebo nights. Int.: Intensity; Unp.: 
Unpleasantness. Paired T-test comparing the placebo and control 
condition: *** p<0.001, ** p<0.01, * p<0.05. 
 
3.4 Sleep Architecture 
 
3.4.1 Polysomnographic Parameters 
 
Sleep parameters were calculated from the polysomnographic recordings for 
each overnight session (Table 1). No significant difference in any parameter was 
observed between the 3 nights (all p’s > 0.05), suggesting that sleep architecture 
was generally stable across sessions. One participant showed longer sleep 
latency (more than 2 standard deviations above the mean) with correspondingly 
shorter sleep duration and poorer sleep efficiency (more than 2 standard 
deviations below the group mean) on the control night, and was therefore 
removed from the analysis of these three variables. 
 




Table 1 Sleep parameters recorded with polysomnography during the 3 nights 
(Mean ± SEM). 
 Habituation night Control night Placebo night 
Sleep latency (min) 12.5 ± 2.7 10.8 ± 3.2 9.9 ± 3.1 
REM sleep latency 
(min) 
102.5 ± 14.8 96.5 ± 18.2 99.0 ± 13.4 
Sleep duration (min) 418.8 ± 12.9 397.1 ± 7.3 410.6 ± 11.7 
Sleep efficiency (%) 93.1 ± 1.6 90.8 ± 1.2 91.4 ± 1.6 
Stage 2 (%) 56.8 ± 2.1 53.4 ± 2.5 52.8 ± 1.8 
SWS (%) 21.3 ± 2.5 20.8 ± 3.0 21.4 ± 2.4 
REM (%) 17.8 ± 2.0 19.9 ± 2.3 21.0 ± 1.5 
Note: One outlier with values outside the range defined by the group mean ± 2 
standard deviations was excluded from the analyses of sleep latency, sleep 
duration, and sleep efficiency for the control night. 
 
3.4.2 Brain Arousal Responses 
 
To assess the effect of placebo manipulation on sleep disturbance, nocturnal 
stimulations were comparably distributed across sleep stages in the control and 
placebo nights (Table 2; Paired T-tests between the total number of stimulations 
per night and per sleep stage, all p’s > 0.49). Whereas the proportion of arousals 
produced by the noxious stimuli applied in stage 2 sleep was comparable 
between the placebo and control nights (Yates corrected 2 (1) =0.09, p=0.77), 
significant differences were found for REM sleep and SWS. During REM sleep, 
placebo treatment was associated with lower arousal rates (83.2%) compared 
with the control night (93.0%; Yates corrected 2(1)=4.49, p=0.034). Conversely, 
during SWS, a significantly higher arousal rate was observed for the placebo 
(88.8%) compared with the control night (74.8%; Yates corrected 2(1)=5.67, 
p=0.017). This suggests that the responsiveness to nociceptive stimuli was 
modulated differentially by the placebo treatment according to the sleep stage. 





Table 2. Total number of nociceptive stimuli applied and number of brain 
arousals produced during each sleep stage in the control and placebo nights 
across all participants. 
 Total number of 
Stimulations 
Number of brain arousals (% 
of total) 
 Control Placebo Control Placebo 
Stage 2 132 130 126 (95.5%) 126 (96.9%) 
SWS  103 98 77 (74.8%)   87 (88.8%)* 
REM 115 119 107 (93.0%)   99 (83.2%)* 
Total 350 347 310 (88.6%) 312 (89.9%) 
Note: The percentage of responses (% of total) is calculated relative to the total 
number of stimuli administered in each sleep stage for each night. SWS: slow 
wave sleep; REM: rapid-eye-movement sleep.  
* Significant difference in the distribution of arousals between Placebo and 
Control; Yates corrected 2, p<0.05. 
 
3.5 Confirmation of a Diurnal Placebo Effect  
 
For all participants, placebo analgesia was assessed on the last morning after 
the third polysomnography night (see Figures 1 and 3) as a manipulation check. 
In this final placebo test, participants still expected to experience less pain 
following placebo treatment compared with the control condition (expected pain 
intensity relief: T(8)=6.99, p<0.001; expected pain unpleasantness relief: 
T(8)=4.01, p=0.004). In addition, participants reported statistically significant 
reductions in pain intensity during concurrent assessments (T(8)=2.70, p=0.027; 
reduced pain unpleasantness: T(8)=1.80, p=0.109, ns). Retrospective 
assessments confirmed the presence of a significant analgesic effect of the 
placebo on both pain intensity (T(8)=2.98, p=0.018) and pain unpleasantness 
(T(8)=2.80, p=0.023).  






Figure 3. Placebo analgesia observed in the waking state on the last 
morning (manipulation check). Expected, concurrent, and retrospective 
pain intensity and unpleasantness measured at the control and placebo 
sites during the Placebo test block after the third night of testing. Int.: 
Intensity; Unp.: Unpleasantness. Paired T-test comparing the placebo to 




This is the first experimental study to investigate directly placebo analgesia 
during sleep. Results suggest that placebo analgesia manipulations performed 
prior to sleep can modulate the responsiveness to nociceptive stimuli on the 
following night. In addition to significant nocturnal pain relief reported in the 
morning following the placebo treatment, participants showed fewer arousals 
during REM sleep, with an unexpected increase during SWS. This suggests that 
the lower nocturnal pain and fewer sleep disturbances reported following placebo 
induction may be due to effects during REM sleep but not SWS. 
 
Several clinical trials have shown improvements in placebo groups relative to 
pre-treatment baseline in self-reported pain and behavioral measures of sleep 




interference (e.g., [21;54]; [12]; [24]). In addition, meta-analytic reviews have 
confirmed robust placebo effects in diseases such as insomnia and restless legs 
syndrome ([40]; [47]; [7]; [23]). A study of fibromyalgia provided further evidence 
that changes in pain after the administration of a placebo treatment were highly 
correlated with measures of sleep quality and sleep disturbance ([57]), 
suggesting that the placebo analgesia effects may generalize to nocturnal pain 
and/or relate to improved sleep. 
 
Experimental studies using auditory evoked potentials have demonstrated that 
electrophysiological features associated with the detection of salient or deviant 
stimuli during waking states are also observed during sleep, but in REM sleep 
exclusively ([6]; [50];[18]). Pre-sleep instructions to engage participant attention 
and threats of electric shock to induce motivation can also modulate the 
amplitude of brain potentials evoked by deviant stimuli as well as the accuracy of 
behavioral responses during REM sleep ([67]; [60]). Accordingly, the reduction in 
the responsiveness to noxious heat following placebo administration in the 
present study was observed exclusively during REM sleep. In line with our 
previous findings ([33]), this suggests that REM sleep plays a role in processing 
expectations, which may in turn modulate responses to nocturnal sensory inputs. 
 
During SWS, the placebo treatment was associated with an unexpectedly higher 
proportion of sleep arousals induced by the nociceptive stimuli. More arousals in 
SWS on the placebo night may reflect the discrepancy between bottom-up 
nociceptive signals registered by the brain and the expectations that these 
noxious stimuli would be less painful (i.e., high prediction error). Reciprocally, 
noxious inputs congruent with expectations on the control night might involve 
more efficient gating mechanisms to protect SWS against inopportune sleep 
disturbances, consistent with basic energy conservation principles central to 
some functional theories of sleep (e.g., [58]; [55]).  
 




Some limitations of the present study should be considered in interpreting those 
findings. The assessment of nocturnal pain, anxiety and sleep disturbances was 
based on retrospective reports obtained in the morning. This procedure is difficult 
to circumvent in sleep research and it may introduce confounding effects 
associated with memory distortions and biases. Furthermore, the within-subject 
design with three recording nights allowed detecting significant placebo-related 
effects in brain arousals during sleep but the sample size is admittedly small. 
Results are nevertheless consistent with our previous findings ([33]) and with the 
current knowledge on placebo effects and the role of REM sleep in learning and 
memory ([34]). Future polysomnographic studies are needed to confirm these 
effects in larger samples and diverse populations, including patients suffering 
from painful conditions. 
 
In this study, the observation that placebo analgesia resulted in lower nocturnal 
pain and anxiety and fewer sleep disturbances suggests that conditioning effects 
and suggestions given before sleep remain active during sleep to some extent. 
Such effects merit further attention, particularly in clinical practice, where patients 
may have positive or negative expectations. The association between chronic 
pain and poor sleep is well-recognized (e.g. [22;30]), and may relate to poor 
expectations developed through learning processes. The fundamental role of 
learning in pain chronification is gaining support (e.g., [5];[61;62]). Such learning 
models integrate the basic theoretical notion of expectation ([26]), which is also a 
key factor in predicting various clinical outcomes (e.g., [41] [20] [17]). The present 
findings should motivate a deeper examination of the role of sleep stages in the 
consolidation of learned expectations and in modulating responses to pain 
treatments during both sleep and waking state.   
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